NeuBase Therapeutics hires chief technology officer

NeuBase Therapeutics has picked up a veteran of the biopharmaceutical industry as its new chief technology officer. NeuBase (Nasdaq: NBSE), a Pittsburgh-based developer of precision genetic medicines, named Anthony Rossomando as the post. He has 25 years of experience in biologics and peptide molecules as well as clinical trial and commercialization experience. He had been chief process development officer at P inetree Therapeutics, and has also held positions at Bayer, Alnylam Pharmaceuticals, Alexion…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news